First-trimester maternal serum levels of sFLT1, PGF and ADMA predict preeclampsia

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Bian, Zheng ^a   Shixia, Chenzi ^a   Duan, Tao ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; N(G),N(G) DIMETHYLARGININE; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; ARGININE; FLT1 PROTEIN, HUMAN; N,N-DIMETHYLARGININE; PGF PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DOPPLER FLOWMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PREECLAMPSIA; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SECOND TRIMESTER PREGNANCY; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BLOOD; BLOOD PRESSURE; DEMOGRAPHY; DIAGNOSTIC IMAGING; ECHOGRAPHY; FOLLOW UP; PHYSIOLOGY; PRE-ECLAMPSIA; PREGNANCY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; UTERINE ARTERY;

ADULT; AREA UNDER CURVE; ARGININE; BLOOD PRESSURE; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PROSPECTIVE STUDIES; ROC CURVE; ULTRASONOGRAPHY; UTERINE ARTERY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84928538773     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124684     Document Type: Article

References (37)

1. Lindheimer MD, Taler SJ, Cunningham FG, American Society of H. ASH position paper: hypertension in pregnancy. J Clin Hypertens (Greenwich). 2009; 11: 214-225. doi: 10.1111/j.1751-7176.2009.00085.x PMID: 19614806
2. American College of O, Gynecologists and Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013; 122: 1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88 PMID: 24150027
3. Yanqiu G, Ronsmans C, Lin A. Time trends and regional differences in maternal mortality in China from 2000 to 2005. Bull World Health Organ. 2009; 87: 913-920. doi: 10.2471/BLT.08.060426 PMID: 20454482
4. Leeman L, Fontaine P. Hypertensive disorders of pregnancy. Am Fam Physician. 2008; 78: 93-100. PMID: 18649616
5. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005; 365: 785-799. PMID: 15733721
6. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Canadian Hypertensive Disorders of Pregnancy Working G. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014; 36: 416-441. PMID: 24927294
7. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003; 102: 181-192. PMID: 12850627
8. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001; 357: 53-56. PMID: 11197372
9. Roberts JM. Preeclampsia: what we know and what we do not know. Semin Perinatol. 2000; 24: 24-28. PMID: 10709854
10. Sibai BM. Biomarker for hypertension-preeclampsia: are we close yet? Am J Obstet Gynecol. 2007; 197: 1-2. PMID: 17618741
11. Cedergren MI. Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstet Gynecol. 2004; 103: 219-224. PMID: 14754687
12. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ. 2011; 342: d1875. doi: 10.1136/bmj.d1875 PMID: 21474517
13. Gallos ID, Sivakumar K, Kilby MD, Coomarasamy A, Thangaratinam S, Vatish M. Pre-eclampsia is associated with, and preceded by, hypertriglyceridaemia: a meta-analysis. BJOG. 2013; 120: 1321-1332. doi: 10.1111/1471-0528.12375 PMID: 23859707
14. Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindheimer M. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol. 2007; 109: 168-180. PMID: 17197602
15. Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol. 2008; 111: 1403-1409. doi: 10.1097/AOG.0b013e3181719b7a PMID: 18515525
16. Nilsen RM, Bjorke-Monsen AL, Midttun O, Nygard O, Pedersen ER, Ulvik A, et al. Maternal tryptophan and kynurenine pathway metabolites and risk of preeclampsia. Obstet Gynecol. 2012; 119: 1243-1250. doi: 10.1097/AOG.0b013e318255004e PMID: 22617590
17. D'Anna R, Baviera G, Corrado F, Giordano D, Di Benedetto A, Jasonni VM. Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders. Obstet Gynecol. 2005; 106: 340-344. PMID: 16055585
18. Noorbakhsh M, Kianpour M, Nematbakhsh M. Serum levels of asymmetric dimethylarginine, vascular endothelial growth factor, and nitric oxide metabolite levels in preeclampsia patients. ISRN Obstet Gynecol. 2013; 2013: 104213. doi: 10.1155/2013/104213 PMID: 24109515
19. Holmes VA, Young IS, Patterson CC, Pearson DW, Walker JD, Maresh MJ, et al. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes Care. 2011; 34: 1683-1688. doi: 10.2337/dc11-0244 PMID: 21636798
20. Robertson WB, Brosens I, Dixon HG. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol. 1967; 93: 581-592. PMID: 6054058
21. Campbell S, Black RS, Lees CC, Armstrong V, Peacock JL. Doppler ultrasound of the maternal uterine arteries: disappearance of abnormal waveforms and relation to birthweight and pregnancy outcome. Acta Obstet Gynecol Scand. 2000; 79: 631-634. PMID: 10949225
22. Campbell S, Diaz-Recasens J, Griffin DR, Cohen-Overbeek TE, Pearce JM, Willson K, et al. New doppler technique for assessing uteroplacental blood flow. Lancet. 1983; 1: 675-677. PMID: 6132039
23. Papageorghiou AT, Yu CK, Bindra R, Pandis G, Nicolaides KH. Fetal Medicine Foundation Second Trimester Screening G. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol. 2001; 18: 441-449. PMID: 11844162
24. Vainio M, Kujansuu E, Koivisto AM, Maenpaa J. Bilateral notching of uterine arteries at 12-14 weeks of gestation for prediction of hypertensive disorders of pregnancy. Acta Obstet Gynecol Scand. 2005; 84: 1062-1067. PMID: 16232173
25. Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol. 2007; 29: 128-134. PMID: 17149788
26. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350: 672-683. PMID: 14764923
27. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003; 188: 177-182. PMID: 12548214
28. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol. 2001; 184: 1267-1272. PMID: 11349200
29. Su YN, Lee CN, Cheng WF, Shau WY, Chow SN, Hsieh FJ. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol. 2001; 97: 898-904. PMID: 11384693
30. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111: 649-658. PMID: 12618519
31. Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004; 50: 1702-1703. PMID: 15331514
32. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol. 2004; 191: 1240-1246. PMID: 15507947
33. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003; 361: 1511-1517. PMID: 12737861
34. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005; 330: 565. PMID: 15743856
35. Metz TD, Allshouse AA, Euser AG, Heyborne KD. Preeclampsia in high risk women is characterized by risk group-specific abnormalities in serum biomarkers. Am J Obstet Gynecol. 2014.
36. Lapaire O, Shennan A, Stepan H. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol. 2010; 151: 122-129. doi: 10.1016/j.ejogrb.2010.04.009 PMID: 20457483
37. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, et al. Early Pregnancy Prediction of Preeclampsia in Nulliparous Women, Combining Clinical Risk and Biomarkers: The Screening for Pregnancy Endpoints (SCOPE) International Cohort Study. Hypertension. 2014; 64: 644-652. doi: 10.1161/HYPERTENSIONAHA.114.03578 PMID: 25122928